Aktienanalyse zu Alto Neuroscience Inc (ANRO)ANROAlto Neuroscience Inc

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alto Neuroscience Inc (ANRO) is currently trading at $21.94, which is below several analyst price targets, such as $37 from BTIG. However, the stock has a low RSI of 27.044, indicating it may be oversold. Despite a strong year-to-date change of +32.25% and a one-year change of +99.45%, the company is facing significant losses, with a net income of -$27.6 million reported in Q2 2026. The main risk is the widening losses, which could deter potential investors.